OpenLB
Open Library of Bioscience
Advanced Search
Rheumatology international
Apr, 2022;42 (4): 639-650.

The effects of golimumab on patient centric outcomes amongst rheumatoid arthritis patients in Greece. The GO-Q study.

Dimitrios Psaltis, Loukas Settas, Athanasios Georgiadis, Eftichia Koukli, Andreas Bounas, Achilleas Livieratos, Evangelia Petrikkou, Heleni Kalogiannaki, Argyro Repa, Dimitrios Vassilopoulos, Prodromos Sidiropoulos
Author Information
  1. Dimitrios Psaltis: Private Practice, Serres, Greece. ORCID
  2. Loukas Settas: University of Thessaloniki, Thessaloniki, Greece.
  3. Athanasios Georgiadis: Private Practice, Ioannina, Greece. ORCID
  4. Eftichia Koukli: Private Practice, Athens, Greece.
  5. Andreas Bounas: OLYMPION"-General Clinic of Patra, Patras, Greece.
  6. Achilleas Livieratos: MSD Pharmaceutical, Industrial and Commercial S.A., Medical Affairs, Athens, Greece. ORCID
  7. Evangelia Petrikkou: MSD Pharmaceutical, Industrial and Commercial S.A., Medical Affairs, Athens, Greece.
  8. Heleni Kalogiannaki: Department of Rheumatology, Clinical Immunology and Allergy, University of Crete Medical School, Heraklion, Greece.
  9. Argyro Repa: Department of Rheumatology, Clinical Immunology and Allergy, University of Crete Medical School, Heraklion, Greece. ORCID
  10. Dimitrios Vassilopoulos: 2nd Department of Medicine and Laboratory Clinical Immunology-Rheumatology Unit, Hippokration General Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece. ORCID
  11. Prodromos Sidiropoulos: Department of Rheumatology, Clinical Immunology and Allergy, University of Crete Medical School, Heraklion, Greece. sidiropp@uoc.gr. ORCID
PMID: 35091757 DOI: 10.1007/s00296-021-05073-1

Abstract

This study aimed at assessing the impact of golimumab on health-related quality of life (HRQoL) and other patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA) in real-world settings. GO-Q was an observational, prospective, 12-month study, which recruited patients with moderate-to-severely active RA initiating golimumab treatment per label in rheumatology clinics and private practices. Primary endpoint was the change in PROs [EuroQol-5 Dimensions-3 Levels (EQ-5D-3L) questionnaire, Health Assessment Questionnaire Disease Index (HAQ-DI), and Work Productivity and Activity Index for RA (WPAI:RA)] after 12 months of treatment. Other endpoints included Disease Activity Score for 28 joints with erythrocyte sedimentation rate (DAS28-ESR), healthcare resource utilization, and golimumab adherence. Changes in continuous variables from baseline were evaluated with the paired t test. One hundred forty-five patients were recruited. The mean [standard deviation (SD)] EQ-5D-3L index increased significantly at 12 months versus baseline [from 0.427 (0.206) to 0.801 (0.229); p < 0.0001], with changes as early as 3 and 6 months (both p < 0.0001). Accordingly, there were statistically significant changes in all WPAI:RA domains from baseline to 3, 6, and 12 months (p < 0.0001). Patients' function improved gradually from the third month until the end of follow-up (p < 0.0001 for all time-points). Thirty (27.3%) and 60 (54.6%) patients achieved remission (DAS28-ESR < 2.6) and low disease activity (DAS28-ESR ≤ 3.2), respectively, at 12 months. Adherence rate to golimumab was high (mean [SD] 90.3% (7.5) at 12 months). In patients with moderate-to-severely active RA, golimumab significantly improved HRQoL, physical function, and work productivity and activity, with improvements in disease activity over 12 months in real-world settings.

Keywords

Effectiveness Golimumab Health-related quality of life Patient-reported outcomes Real-world study Rheumatoid arthritis

References

Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet 388(10055):2023–2038. https://doi.org/10.1016/S0140-6736(16)30173-8 [DOI: 10.1016/S0140-6736(16)30173-8]
Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G et al (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69(4):631–637. https://doi.org/10.1136/ard.2009.123919 [DOI: 10.1136/ard.2009.123919]
Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79(6):685–699. https://doi.org/10.1136/annrheumdis-2019-216655 [DOI: 10.1136/annrheumdis-2019-216655]
Aletaha D, Landewe R, Karonitsch T, Bathon J, Boers M, Bombardier C et al (2008) Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis 67(10):1360–1364. https://doi.org/10.1136/ard.2008.091454 [DOI: 10.1136/ard.2008.091454]
Gossec L, Dougados M, Dixon W (2015) Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis. RMD Open 1(1):e000019. https://doi.org/10.1136/rmdopen-2014-000019 [DOI: 10.1136/rmdopen-2014-000019]
Fautrel B, Alten R, Kirkham B, de la Torre I, Durand F, Barry J, Holzkaemper T et al (2018) Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis. Rheumatol Int 38(6):935–947. https://doi.org/10.1007/s00296-018-4005-5 [DOI: 10.1007/s00296-018-4005-5]
Senolt L (2019) Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies. F1000Res. https://doi.org/10.12688/f1000research.18688.1 [DOI: 10.12688/f1000research.18688.1]
Hamann PDH, Pauling JD, McHugh N, Shaddick G, Hyrich K, BSRBR-RA Contributors Group (2019) Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor-treated rheumatoid arthritis patients. Rheumatology (Oxford) 58:2162–2169. https://doi.org/10.1093/rheumatology/kez188 [DOI: 10.1093/rheumatology/kez188]
Chatzidionysiou K (2020) Beyond methotrexate and biologics in RA—efficacy of JAK inhibitors and their place in the current treatment armamentarium. Mediterr J Rheumatol 31(1):120–128. https://doi.org/10.31138/mjr.31.1.120 [DOI: 10.31138/mjr.31.1.120]
Genitsaridi I, Flouri I, Plexousakis D, Marias K, Boki K, Skopouli F et al (2020) Rheumatoid arthritis patients on persistent moderate disease activity on biologics have adverse 5-year outcome compared to persistent low-remission status and represent a heterogeneous group. Arthritis Res Ther 22(1):226. https://doi.org/10.1186/s13075-020-02313-w [DOI: 10.1186/s13075-020-02313-w]
Taylor PC, Moore A, Vasilescu R, Alvir J, Tarallo M (2016) A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatol Int 36(5):685–695. https://doi.org/10.1007/s00296-015-3415-x [DOI: 10.1007/s00296-015-3415-x]
Strand V, Singh JA (2010) Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity. Drugs 70(2):121–145. https://doi.org/10.2165/11531980-000000000-00000 [DOI: 10.2165/11531980-000000000-00000]
El Miedany Y, El Gaafary M, El Arousy N, Ahmed I, Youssef S, Palmer D (2012) Arthritis education: the integration of patient-reported outcome measures and patient self-management. Clin Exp Rheumatol 30(6):899–904 [PMID: 22992291]
Uhlig T, Loge JH, Kristiansen IS, Kvien TK (2007) Quantification of reduced health-related quality of life in patients with rheumatoid arthritis compared to the general population. J Rheumatol 34(6):1241–1247 [PMID: 17516624]
Pincus T, Sokka T (2003) Quantitative measures for assessing rheumatoid arthritis in clinical trials and clinical care. Best Pract Res Clin Rheumatol 17(5):753–781 [DOI: 10.1016/S1521-6942(03)00077-9]
European Medicines Agency. Simponi. https://www.ema.europa.eu/en/documents/product-information/simponi-epar-product-information_en.pdf . Accessed 11 Dec 2020
Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P et al (2009) Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naïve patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 60(8):2272–2283. https://doi.org/10.1002/art.24638 [DOI: 10.1002/art.24638]
Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC et al (2009) Golimumab, a human antibody to tumour necrosis factor alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 68(6):789–796. https://doi.org/10.1136/ard.2008.099010 [DOI: 10.1136/ard.2008.099010]
Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J et al (2009) Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicenandomizedmised, double-blind, placebo-controlled, phase III trial. Lancet 374(9685):210–221. https://doi.org/10.1016/S0140-6736(09)60506-7 [DOI: 10.1016/S0140-6736(09)60506-7]
Genovese MC, Han C, Keystone EC, Hsia EC, Buchanan J, Gathany T et al (2012) Effect of golimumab on patient-reported outcomes in rheumatoid arthritis: results from the GO-FORWARD study. J Rheumatol 39(6):1185–1191. https://doi.org/10.3899/jrheum.111195 [DOI: 10.3899/jrheum.111195]
Hernandez MV, Sanchez-Piedra C, Garcia-Magallon B, Cuende E, Manero J, Campos-Fernandez C et al (2019) Factors associated with long-term retention of treatment with golimumab in a real-world setting: an analysis of the Spanish BIOBADASER registry. Rheumatol Int 39(3):509–515. https://doi.org/10.1007/s00296-018-4177-z [DOI: 10.1007/s00296-018-4177-z]
Pombo M, Sánchez-Piedra C, Cea-Calvo L et al (2020) FRI0290 factors associated with persistence of golimumab treatment in the BIOBADASER registry, up to 7 years of follow-up. Ann Rheum Dis 79:733–734 [DOI: 10.1136/annrheumdis-2020-eular.3490]
Dejaco C, Mueller T, Zamani O, Kurtz U, Egger S, Resch-Passini J et al (2018) Golimumab improves work productivity and activity as well as quality of life in patients with rheumatoid arthritis (RA), psoriasis arthritis (PsA) and axial spondyloarthritis (axSpA): interim results from a non-interventional study in Austria (go active) [abstract]. In2018 ACR/ARHP Annual Meeting 2018, Arthritis Rheumatol, 70 (suppl 10)
Krüger K, Burmester GR, Wassenberg S, Bohl-Bühler M, Thomas MH (2019) Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany. Rheumatol Int 39(1):131–140. https://doi.org/10.1007/s00296-018-4180-4 [DOI: 10.1007/s00296-018-4180-4]
Iannone F, Favalli EG, Caporali R, D’Angelo S, Cantatore FP, Sarzi-Puttini P et al (2021) Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA. Joint Bone Spine 88(1):105062. https://doi.org/10.1016/j.jbspin.2020.07.011 [DOI: 10.1016/j.jbspin.2020.07.011]
Krueger K, Remstedt S, Thiele A, Hohenberger S (2020) Golimumab improves patient-reported outcomes in daily practice of inflammatory rheumatic diseases in Germany. J Comp Eff Res 9(12):891–902. https://doi.org/10.2217/cer-2020-0092 [DOI: 10.2217/cer-2020-0092]
Mourão AF, Ribeiro C, Borges J, Gonçalves MJ, Bernardes M, Fernandes S et al (2017) Real-life effectiveness of Golimumab in biologic-naïve patients with rheumatoid arthr–tis—data from the rheumatic diseases portuguese register (Reuma.pt). Acta Reumatol Port 42:141–149 [PMID: 28371797]
Krüger K, Burmester GR, Wassenberg S, Bohl-Bühler M, Thomas MH (2018) Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany. BMJ Open 8(6):e021082. https://doi.org/10.1136/bmjopen-2017-021082 [DOI: 10.1136/bmjopen-2017-021082]
Krüger K, Burmester GR, Wassenberg S, Thomas MH (2020) Golimumab as the first, second-, or at least third-line biologic agent in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis: post hoc analysis of a noninterventional study in Germany. Rheumatol Ther 7(2):371–382. https://doi.org/10.1007/s40744-020-00204-9 [DOI: 10.1007/s40744-020-00204-9]
Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–324. https://doi.org/10.1002/art.1780310302 [DOI: 10.1002/art.1780310302]
Fransen J, van Riel PL (2005) The disease activity score and the EULAR response criteria. Clin Exp Rheumatol 23(5 Suppl 39):S93-99. https://doi.org/10.1016/j.rdc.2009.10.001 [DOI: 10.1016/j.rdc.2009.10.001]
EuroQol Group (1990) EuroQol—a new facility for the measurement of health-related quality of life. Health Policy 16:199–208. https://doi.org/10.1016/0168-8510(90)90421-9 [DOI: 10.1016/0168-8510(90)90421-9]
Brooks R (1996) EuroQol: the current state of play. Health Policy 37:53–72. https://doi.org/10.1016/0168-8510(96)00822-6 [DOI: 10.1016/0168-8510(96)00822-6]
EuroQol Group. EQ-5D-3L User Guide. https://euroqol.org/publications/user-guides/ Accessed 09 Nov 2021
Bruce B, Fries JF (2005) The health assessment questionnaire (HAQ). Clin Exp Rheumatol 23(39):S14-18 [PMID: 16273780]
Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 4:353–365. https://doi.org/10.2165/00019053-199304050-00006 [DOI: 10.2165/00019053-199304050-00006]
Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38(1):44–48. https://doi.org/10.1002/art.1780380107 [DOI: 10.1002/art.1780380107]
Wen H, Ralph Schumacher H, Li X, Gu J, Ma L, Wei H et al (2012) Comparison of expectations of physicians and patients with rheumatoid arthritis for rheumatology clinic visits: a pilot, multicenter, international study. Int J Rheum Dis 15(4):380–389. https://doi.org/10.1111/j.1756-185X.2012.01752.x [DOI: 10.1111/j.1756-185X.2012.01752.x]
Nemoto T, Ito S, Kobayashi D, Takai C, Sakai S, Kurosawa Y et al (2021) Long-term use of golimumab in daily practice for patients with rheumatoid arthritis. Intern Med 60(9):1359–1367. https://doi.org/10.2169/internalmedicine.5381-20 (Erratum in: Intern Med. 2021;60(13):2163) [DOI: 10.2169/internalmedicine.5381-20]
Akar S, Kalyoncu U, Dalkilic E, Emmungil H, Aziz A, Esen Y, Koc T (2021) GO-BEYOND: a real-world study of persistence of golimumab in patients with axial spondyloarthritis and rheumatoid arthritis in Turkey. Immunotherapy 13(10):841–850. https://doi.org/10.2217/imt-2020-0296 [DOI: 10.2217/imt-2020-0296]
Nieto JC, Arajol C, Carmona L, Marras C, Cea-Calvo L (2021) Adherence to subcutaneous biological therapies in patients with inflammatory rheumatic diseases and inflammatory bowel disease: a systematic review. Immunotherapy 13(5):433–458. https://doi.org/10.2217/imt-2021-0011 [DOI: 10.2217/imt-2021-0011]
Calvo-Alén J, Monteagudo I, Salvador G, Vázquez-Rodríguez TR, Tovar-Beltrán JV, Vela P, Maceiras F et al (2017) Non-adherence to subcutaneous biological medication in patients with rheumatoid arthritis: a multicentre, non-interventional study. Clin Exp Rheumatol 35(3):423–430 [PMID: 28032846]
Stolshek BS, Wade S, Mutebi A, De AP, Wade RL, Yeaw J (2018) Two-year adherence and costs for biologic therapy for rheumatoid arthritis. Am J Manag Care 24:SP315–SP321 [PMID: 30020744]
Sato E, Tanaka E, Ochiai M, Shimizu Y, Kobayashi A, Shidara K et al (2015) Chronological changes in baseline disease activity of patients with rheumatoid arthritis who received biologic DMARDs between 2003 and 2012. Mod Rheumatol 25(3):350–357. https://doi.org/10.3109/14397595.2014.958274 [DOI: 10.3109/14397595.2014.958274]
Ingegnoli F, Castelli R, Gualtierotti R (2013) Rheumatoid factors: clinical applications. Dis Markers 35(6):727–734. https://doi.org/10.1155/2013/726598 [DOI: 10.1155/2013/726598]
Eker YÖ, Pamuk ÖN, Pamuk GE, Dönmez S, Çakır N (2014) The Frequency of anti-CCP antibodies in patients with rheumatoid arthritis and psoriatic arthritis and their relationship with clinical features and parameters of angiogenesis: a comparative study. Eur J Rheumatol 1(2):67–71. https://doi.org/10.5152/eurjrheumatol.2014.022 [DOI: 10.5152/eurjrheumatol.2014.022]
Nikiphorou E, Sjöwall C, Hannonen P, Rannio T, Sokka T (2016) Long-term outcomes of destructive seronegative (rheumatoid) arthritis—description of four clinical cases. BMC Musculoskelet Disord 3(17):246. https://doi.org/10.1186/s12891-016-1067-y [DOI: 10.1186/s12891-016-1067-y]
Johnston BC, Patrick DL, Devji T, Maxwell LJ, Bingham III CO, Beaton D, Boers M et al (2021) Chapter 18: Patient-reported outcomes. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). Cochrane. Available from www.training.cochrane.org/handbook . Accessed 06 July 2021
Kontodimopoulos N, Pappa E, Niakas D, Yfantopoulos J, Dimitrakaki C, Tountas Y (2008) Validity of the EuroQoL (EQ-5D) instrument in a greek general population. Value In Health 11(7):1162–1169. https://doi.org/10.1111/j.1524-4733.2008.00356.x [DOI: 10.1111/j.1524-4733.2008.00356.x]

MeSH Term

Antibodies, Monoclonal
Antirheumatic Agents
Arthritis, Rheumatoid
Greece
Humans
Patient-Centered Care
Prospective Studies
Quality of Life
Severity of Illness Index
Treatment Outcome

Chemicals

Antibodies, Monoclonal
Antirheumatic Agents
golimumab
Journal Article Observational Study

Word Cloud

Similar Articles

Cited By